Madrid, Spain—Final results from the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial show that dual HER2 blockade with the combination of pertuzumab and trastuzumab plus chemotherapy extended overall survival (OS) by almost 16 months compared with trastuzumab plus chemotherapy alone in patients with HER2-positive metastatic breast cancer. This should become the new standard of care for patients with metastatic HER2 disease, according to the study investigators, who presented their results at the 2014 European Society for Medical Oncology (ESMO) Congress.
Although increasing the reimbursement rate for cancer screening tests does not consistently improve the likelihood of Medicaid beneficiaries being screened for cancer, raising the rate of reimbursement for office visits does consistently increase the likelihood that they will be screened for cancer, including breast or prostate cancer, according to results of a new analysis of Medicaid claims and enrollment data.
New York, NY—In a debate on the role of rituximab (Rituxan) maintenance therapy in patients with follicular lymphoma at the 2014 National Comprehensive Cancer Network Congress, the protagonist and antagonist were not that far apart.
Anew guideline for systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC) is based on a literature review of recent publications and outlines the survival and quality-of-life benefits/toxicity effects of each recommendation.
Toronto, Canada—Survival is not improved with routine surveillance using computed tomography (CT) versus chest x-ray in patients who have undergone resection for stage I non–small-cell lung cancer (NSCLC), according to the results of a new analysis presented at the 2014 American Association for Thoracic Surgery meeting.
San Francisco, CA—The use of stereotactic body radiotherapy (SBRT), also called stereotactic radiotherapy or radiosurgery, is an effective option for elderly patients with cancer who are inoperable or who decline surgery, but its safety and efficacy compared with surgery have not been investigated.
Chicago, IL—The commercially available cell-cycle progression test known as Prolaris is helpful for stratifying risk for men with clinically localized prostate cancer and can help to modify treatment decisions for men with prostate cancer based on the aggressive nature of their tumor, according to a poster presented at the 2014 College of American Pathologists annual meeting by Michael K. Brawer, MD, Vice President of Medical Affairs, Urology, Myriad Genetic Laboratories, Inc, Salt Lake City, UT, and colleagues.
The Merriam-Webster dictionary defines “logistics” as the things that must be done to plan and organize a complicated activity that involves many people. The modern delivery of cancer care precisely parallels this definition.
The initiative to improve end-of-life care in the United States is taking center stage, and it is about time. The US population is aging, and the number of older Americans with comorbidities is growing. In addition, the US population is becoming more culturally diverse, so there is an increased need for more responsive, patient-centered care. Furthermore, the current healthcare system is disjointed, and contains elements that obstruct the delivery of high-quality end-of-life care, according to a new report.
PIK3CA Mutations Associated with Favorable Prognostic Factors in Breast Cancer
Coexistence of BRAF and TERT Mutations Identified in Papillary Thyroid Cancer
Novel Mutations Identified Can Help to Overcome Treatment Resistance in Lung Cancer
Page 1 of 4
Results 1 - 10 of 33
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology